HDAC inhibitors and immunotherapy; a double edged sword?
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
// Michiel Kroesen 1,2 , Paul R. Gielen 1,* , Ingrid C. Brok 1,* , Inna Armandari 1 , Peter M. Hoogerbrugge 2,3 and Gosse J. Adema 1 1 Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands 2 Department of Pediatric Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands 3 Princes Máxima Center for Pediatric Oncology, The Bilt, The Netherlands * These authors contributed equally to this work Correspondence: Gosse J. Adema, email: // Keywords : HDAC inhibitor, cancer, immunotherapy, immunocombination therapy Received : June 27, 2014 Accepted : July 31, 2014 Published : July 31, 2014 Abstract Epigenetic modifications, like histone acetylation, are essential for regulating gene expression within cells. Cancer cells acquire pathological epigenetic modifications resulting in gene expression patterns that facilitate and sustain tumorigenesis. Epigenetic manipulation therefore is emerging as a novel targeted therapy for cancer. Histone Acetylases (HATs) and Histone Deacetylases (HDACs) regulate histone acetylation and hence gene expression. Histone deacetylase (HDAC) inhibitors are well known to affect cancer cell viability and biology and are already in use for the treatment of cancer patients. Immunotherapy can lead to clinical benefit in selected cancer patients, especially in patients with limited disease after tumor debulking. HDAC inhibitors can potentially synergize with immunotherapy by elimination of tumor cells. The direct effects of HDAC inhibitors on immune cell function, however, remain largely unexplored. Initial data have suggested HDAC inhibitors to be predominantly immunosuppressive, but more recent reports have challenged this view. In this review we will discuss the effects of HDAC inhibitors on tumor cells and different immune cell subsets, synergistic interactions and possible mechanisms. Finally, we will address future challenges and potential application of HDAC inhibitors in immunocombination therapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Selected chemotherapeutics can induce so-called “immunogenic cell death”, a process in which dying tumor cells can stimulate cellular uptake, activation and crosspresentation by antigen presenting cells (APCs), thereby inducing antitumor T cell responses[59].”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“Epigenetic changes can occur at multiple levels including direct modifications of the DNA itself as well as modifications of the DNA associated histone proteins[7].”
BackgroundAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 1×
“Immunotherapy is a promising novel cancer therapy for multiple cancer types, including melanoma and neuroblastoma[11, 12].”
BackgroundCaspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 1×
“Furthermore, it will be interesting to compare the potency of Vorinostat and other HDAC inhibitors to induce immunogenic cell death with that of chemotherapeutic agents previously demonstrated to induce immunogenic cell death[64].”
BackgroundHDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069 · cited 4×
“These socalled HDAC inhibitors, are now regarded as a group of anti-cancer drugs with high clinical potential[9, 21, 22].”
BackgroundInfluentialChemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720 · cited 1×
“Indeed, the panHDAC inhibitor TSA has a higher inhibitory potency for most of the individual HDACs compared to Vorinostat, which could explain the more pronounced effects of TSA in the murine CD4 T cells[95-97].”
BackgroundThe histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · cited 2×
“These socalled HDAC inhibitors, are now regarded as a group of anti-cancer drugs with high clinical potential[9, 21, 22].”
BackgroundLauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · cited 1×
“Because each individual HDAC inhibitor has a unique chemical structure and HDAC inhibitory profile, different HDAC inhibitors can cause a large variety of biological effects in cancer cells and in normal cells[32, 33].”
Background
Cited by
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“Inhibition of Class II HDACs enhances number and function of Treg and Class I HDAC inhibitors enhances the functions of NK cells and CD8 T cells [122].”
BackgroundOrillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
“Disease progression is also promoted by the strongly immunosuppres (Treg) cells and myeloid-derived suppressor cells (MDSCs), and increase of the programmed cell death-1 (PD-1) expre cells.”
BackgroundInfluentialHicks, K. C., Knudson, K. M., Lee, K. L., Hamilton, D. H., Hodge, J. W., Figg, W. D., Ordentlich, P., Jones, F. R., Rabizadeh, S., Soon-Shiong, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0727 · Cited by 44
Metadata
- Authors
- Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-07-31
- Volume
- 5
- Issue
- 16
- Pages
- 6558-6572
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1516453481
- Cited by
- 166
- References
- 17
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.